Psyence Biomedical LTD F-1 registration statements

Psyence Biomedical Ltd. files an amended registration statement to allow White Lion Capital to resell up to 50 million common shares, potentially impacting market price.

Psyence Biomedical Ltd. filed an F-1/A registration statement for the potential resale of 50 million common shares by White Lion Capital, an amount vastly exceeding current outstanding shares.

Psyence Biomedical Ltd. has filed a registration statement for the resale of over 3 million common shares, including shares underlying warrants, following a recent private placement.

Psyence Biomedical seeks to register the resale of over 10 million common shares by existing securityholders, including shares related to debt settlements, make-whole obligations, and a purchase agreement with White Lion Capital.

Psyence Biomedical files an F-1 registration statement for the potential resale of up to 104.9 million common shares by selling securityholders, including shares related to the White Lion Capital agreement and PGI swap agreements.

Psyence Biomedical has filed a registration statement for the potential sale of up to 10.9 million common shares, including shares issuable upon conversion of notes and exercise of warrants.

Psyence Biomedical registers for the potential resale of over 50 million common shares by selling securityholders, including shares issuable to White Lion Capital under an equity line of credit.

Psyence Biomedical is seeking to register for resale 22,496,000 common shares and 570,000 warrants, along with the potential issuance of 13,070,000 common shares upon warrant exercise.

Psyence Biomedical seeks to register the resale of a significant number of common shares and warrants following its recent business combination, potentially impacting the market price.

Psyence Biomedical seeks to register the resale of common shares and warrants following its recent business combination, potentially impacting the market price.

Psyence Biomedical Ltd. has filed a registration statement for the resale of approximately 22.5 million common shares by selling shareholders after its recent business combination.